A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

July 24, 2025

Study Completion Date

July 1, 2026

Conditions
Thyroid Eye Disease
Interventions
DRUG

Satralizumab

Satralizumab will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection

Trial Locations (41)

8907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

13620

Seoul National University Bundang Hospital, Seongnam-si

18012

Hospital Universitario Virgen de las Nieves, Granada

19104

Scheie Eye Institute, Philadelphia

28031

Hospital Ramon y Cajal, Madrid

28040

Hospital Universitario Clínico San Carlos, Madrid

37232

Vanderbilt Eye Institute, Nashville

41007

Hospital Universitario Virgen de la Macarena, Seville

44093

CHU Nantes - Hôtel Dieu, Nantes

46026

Hospital Universitario la Fe: Servicio de Oftalmologia, Valencia

60612

University of Illinois Eye and Ear Infirmary, Chicago

75012

CHNO Hopital des Quinze Vingts, Paris

75019

Fondation Rothschild, Paris

78251

Retina Consultants of Texas, San Antonio

92108

Plastics-Orbit-Neuro, San Diego

100032

Peking Union Medical College Hospital, Beijing

100191

Peking University Third Hospital, Beijing

100730

Beijing Hospital of Ministry of Health, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing

710004

Xi'an Fourth Hospital, Xi'an

4941492

Rabin MC, Petah Tikva

9112001

Hadassah MC, Jerusalem

06810

Connecticut Eye Consultants, P.C., Danbury

Unknown

University of Alberta, Edmonton

Sheba medical center, Ramat Gan

M3C 0G9

Toronto Retina Institute, Toronto

H1T 2M4

Universite de Montreal - Hopital Maisonneuve-Rosemont, Montreal

85-316

Specjalistyczny O?rodek Okulistyczny Oculomedica, Bydgoszcz

80-180

Optimum Profesorskie Centrum Okulistyki, Gdansk

3000-548

AIBILI - Association for Innovation and Biomedical Research on Light, Coimbra

003-722

Severance Hospital, Yonsei University Health System, Seoul

06973

Chung-Ang University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

08035

Hospital Universitario Vall d Hebron, Barcelona

BN2 5BF

Sussex Eye Hospital, Brighton

BS1 2LX

Bristol Eye Hospital, Bristol

G12 0YN

Gartnavel General Hospital, Glasgow

LS9 7TF

St James University Hospital, Leeds

L7 8XP

Royal Liverpool University Hospital, Liverpool

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

ME16 9QQ

Maidstone Hospital, Maidstone, Kent

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06106828 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease | Biotech Hunter | Biotech Hunter